Artificial intelligence is moving rapidly from experimentation into pharmaceutical research, clinical development, medical affairs, regulatory operations, and drug safety. As adoption grows, the regulatory question is also changing. It is no longer enough to ask whether an AI system can produce useful outputs. Pharmaceutical companies increasingly need to demonstrate that AI is being used in a controlled, transparent, scientifically appropriate, and risk-based manner.
The phrase FDA's first AI warning letter has attracted attention because it suggests a major enforcement milestone. However, as of August 2026, a review of the FDA's publicly available warning-letter resources does not establish a clearly identified FDA warning letter specifically issued as an enforcement action for a pharmaceutical company's use of AI. FDA does publish warning letters concerning significant violations of federal requirements, including problems involving product claims, manufacturing practices, and directions for use. [1]
That distinction matters. The absence of a verified, AI-specific pharmaceutical warning letter should not be interpreted as an absence of regulatory expectations. In fact, FDA has significantly expanded its AI-related guidance and activities. Its January 2026 guiding principles for good AI practice in drug development emphasise human-centric design, risk-based approaches, clear context of use, data governance, documentation, performance assessment, and lifecycle management. [2]
For regulatory and medical affairs teams, the lesson is clear: an explainable AI platform enterprise approach to AI governance needs to be established before enforcement becomes the primary driver.
Why the FDA AI Warning Letter Question Matters
Warning letters are important because they communicate FDA concerns about potentially significant violations and give recipients an opportunity to respond and correct identified issues. [1]
If an AI-enabled system contributes to a regulated activity, the underlying compliance expectations do not disappear simply because the activity involves an algorithm rather than a traditional software workflow.
For example, pharmaceutical organisations may use AI to:
Analyse clinical trial data
Monitor emerging safety information
Support regulatory intelligence
Review scientific literature
Generate evidence summaries
Assist medical information teams
Analyse competitor clinical programmes
Prepare regulatory documents
Support submissions
Identify potential inconsistencies in scientific content
Each application creates a different risk profile.
An AI system used to organise publicly available literature may require a different level of oversight from a model that generates information used to support a regulatory decision about a drug's safety or effectiveness.
This context-dependent approach is central to FDA's current AI thinking.
What FDA Is Actually Saying About AI in 2026
FDA's current AI position is broader than a single enforcement action.
FDA states that AI use has increased throughout the drug product lifecycle, including nonclinical, clinical, postmarketing, and manufacturing activities. The agency also reports a significant increase in drug application submissions containing AI components. [3]
In January 2026, FDA and EMA published ten guiding principles for good AI practice in drug development. The principles include:
Human-centric design
Risk-based approaches
Adherence to standards
Clear context of use
Multidisciplinary expertise
Data governance and documentation
Appropriate model design and development
Risk-based performance assessment
Lifecycle management
Clear and essential information
[2]
These principles are particularly relevant to pharmaceutical companies building AI systems for regulatory and medical affairs workflows.
The important point is that the FDA framework is not simply asking whether a model is technically impressive. It is asking whether the organisation understands how the model is being used, what evidence supports its performance, what risks exist, and how those risks are managed.
What the FDA's 2025 AI Draft Guidance Means
One of the most important developments for pharmaceutical AI governance is FDA's January 2025 draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.
The draft guidance proposes a risk-based credibility assessment framework for AI models used to produce information or data intended to support regulatory decision-making concerning drug safety, effectiveness, or quality. [4]
The guidance is currently a draft and is explicitly described by FDA as non-binding and not for implementation. [4]
Nevertheless, it provides an important direction for companies.
The central concept is context of use.
An AI model should not be considered credible in isolation. Its credibility needs to be considered in relation to the specific purpose for which it is being used.
For example, an AI system that helps a regulatory professional search documents is fundamentally different from a model whose output directly contributes to an analysis supporting a regulatory conclusion.
The risk associated with the second application may be substantially greater.
This means organisations should avoid creating broad statements such as "our AI model is validated."
A better question is:
Validated for what purpose, using which data, under what conditions, and with what level of human oversight?
What Is FDA AI Guidance 2026 Telling Pharmaceutical Companies?
The current FDA AI guidance 2026 landscape is developing across multiple areas rather than through one comprehensive AI regulation.
The January 2026 good-AI-practice principles are particularly relevant to drug development. FDA has also continued publishing AI-related resources and guidance covering different aspects of medical product development.
For example, FDA's June 2026 final ICH M15 guidance on Model-Informed Drug Development addresses planning, model evaluation, documentation of evidence, regulatory interactions, reporting, and submission considerations for model-informed development. [5]
In addition, FDA's January 2026 final guidance on clinical decision support software clarifies how certain software functions may fall within or outside the statutory definition of a medical device and explains how existing digital health policies apply to software functions that meet the device definition. [6]
These developments show why pharmaceutical organisations should avoid treating "AI compliance" as one isolated checklist.
Different AI applications can interact with different regulatory frameworks depending on their intended purpose.
Why Explainability Matters in Pharmaceutical AI
Explainability becomes particularly important when AI outputs influence scientific or regulatory decisions.
An AI system may provide a highly confident answer, but a regulatory professional needs to understand more than the answer itself.
They may need to know:
Which sources were used
Which data contributed to the output
What assumptions were applied
Whether the model has known limitations
How reliable the output is for the specific use case
Whether the result can be reproduced
What human review occurred
Whether the underlying information remains current
This is why an explainable AI platform enterprise environment can be valuable for regulated organisations.
The goal of explainability is not necessarily to expose every technical detail of a model to every user. Instead, it is to provide enough transparency for users and governance teams to understand the basis, limitations, and appropriate use of AI-generated outputs.
For regulatory and medical affairs teams, this can make the difference between an AI system that simply produces information and one that can operate within a controlled evidence workflow.
AI Compliance Regulatory Affairs: What Teams Should Control
Effective AI compliance regulatory affairs programmes should cover the entire AI lifecycle rather than focusing only on the final output.
1. Define the Intended Use
Every AI application should have a clearly defined purpose.
Teams should document what the system is designed to do, who will use it, what decisions it supports, and what it is explicitly not intended to do.
A narrowly defined use case is easier to assess and govern than a vague instruction to "use AI for regulatory work."
2. Establish the Context of Use
Context determines risk.
An AI system used for internal information retrieval may present a different risk from one used to generate evidence incorporated into a regulatory submission.
The organisation should establish the relationship between the AI output and the eventual decision.
3. Govern the Data
AI performance depends heavily on the information used by the system.
Teams should understand:
Data governance should be documented rather than assumed.
AI performance can change over time.
Changes in data, models, prompts, integrations, or external information can affect outputs.
Organisations should therefore establish appropriate performance monitoring and review processes.
5. Maintain Human Oversight
Human review remains an important safeguard for higher-risk applications.
The reviewer should understand the AI system's intended purpose and limitations rather than simply approving whatever output it produces.
6. Preserve Documentation
Documentation should make it possible to reconstruct important decisions about an AI system.
This can include:
Model information
Data sources
Intended use
Validation activities
Performance results
Known limitations
Changes over time
Human review procedures
Governance approvals
7. Create an Audit Trail
A regulated organisation should be able to establish what happened when an AI-assisted workflow produced an important output.
This is particularly important when AI contributes to regulatory submissions, safety assessments, medical content, or other high-impact processes.
The same principles apply to medical affairs AI tools.
Medical affairs teams are using AI for literature monitoring, evidence synthesis, medical information, scientific intelligence, KOL research, congress monitoring, and internal knowledge discovery.
These applications can generate substantial efficiency gains.
However, medical affairs teams should distinguish between information assistance and scientific decision-making.
For example, AI can help retrieve publications and summarise study characteristics. A medical professional should still evaluate whether the evidence has been interpreted correctly.
Similarly, AI can identify emerging scientific developments, but the medical team should determine their actual significance.
This creates a useful operating principle:
AI can accelerate evidence processing without becoming the final scientific authority.
AI in Regulatory Intelligence
Regulatory intelligence is another area where AI can provide significant value.
Regulatory professionals may need to monitor:
AI can help organise this information and identify potentially relevant changes.
However, regulatory intelligence requires a strong distinction between source information and AI interpretation.
A regulatory professional should be able to return to the original document and verify an important claim.
This is particularly important when guidance is evolving.
An AI system trained on older information could otherwise present outdated regulatory expectations as if they were current.
Pienomial and Governed AI for Life Sciences
Pienomial can support life sciences organisations seeking to build a more structured approach to AI-powered intelligence.
Its life sciences intelligence platform approach connects AI with evidence and intelligence workflows, helping teams work across complex scientific and competitive information environments.
For regulatory, medical affairs, and other high-stakes teams, AI-generated intelligence should remain grounded in verified evidence, traceable to its sources, and subject to appropriate expert review. Pienomial also supports private deployments and controlled data environments, helping organisations maintain governance and control over sensitive knowledge.
This governed knowledge foundation can support multiple AI workflows while enabling teams to reuse consistent, trusted intelligence instead of managing separate tools with fragmented data and governance.
The broader Pienomial platform can also provide a common foundation for AI-enabled workflows rather than requiring every team to adopt disconnected tools with different governance practices.
The value is not simply automation.
It is the combination of AI, evidence, transparency, and appropriate human oversight.
Preparing for Future FDA Enforcement
Even if there is not yet a clearly verified pharmaceutical FDA warning letter specifically focused on AI use, companies should not wait for one to establish internal controls.
A future enforcement action could potentially focus on traditional regulatory violations where AI played a role.
For example, risk could arise if AI contributes to:
Misleading promotional claims
Inaccurate regulatory information
Unsupported scientific statements
Inadequate documentation
Incorrect safety information
Deficient quality systems
Inappropriate data handling
Uncontrolled automated decision-making
The lesson is therefore broader than "avoid an AI warning letter."
Companies should ensure that AI-assisted processes meet the same standards of scientific integrity, documentation, accuracy, and oversight expected of other regulated processes.
A Practical AI Governance Framework for Pharma
Pharmaceutical companies can establish a practical governance framework around six questions.
What Is the AI Used For?
Document the specific business and scientific purpose.
What Evidence Does It Use?
Identify data sources and establish their quality and provenance.
What Could Go Wrong?
Assess risks associated with incorrect, incomplete, biased, outdated, or misleading outputs.
Establish appropriate testing and monitoring based on the intended use.
Who Reviews the Output?
Define human responsibilities and escalation procedures.
How Is Everything Documented?
Maintain records covering the system, data, validation, changes, outputs, and relevant decisions.
This approach allows organisations to scale AI without treating every application as identical.
Why Enterprise AI Governance Needs to Be Explainable
As AI adoption grows, governance cannot remain entirely manual.
Large pharmaceutical organisations may eventually have dozens or hundreds of AI-enabled workflows across research, clinical development, medical affairs, regulatory affairs, pharmacovigilance, commercial operations, and other functions.
Managing these applications individually can create governance fragmentation.
An enterprise AI environment can provide common controls for:
User access
Data permissions
Source governance
AI workflows
Human review
Audit trails
Model documentation
Performance monitoring
Risk classification
This is where an enterprise explainable AI platform can become strategically useful.
The platform should not simply tell an organisation that AI was used. It should help establish how the AI was used, what information supported the output, what controls applied, and where human judgment entered the process.
Conclusion
The discussion around the FDA's first AI warning letter reflects a broader concern within pharmaceutical organisations: when will AI use become an explicit focus of regulatory enforcement?
As of August 2026, publicly available FDA warning-letter resources do not establish a clearly identified pharmaceutical warning letter specifically issued for AI use. But that does not mean organisations have a regulatory blank cheque.
FDA is actively developing its approach to AI across drug development and medical products. Its January 2026 guiding principles emphasise human-centric design, risk-based approaches, context of use, data governance, performance assessment, and lifecycle management. [2]
For pharmaceutical companies, the sensible response is to establish governance before enforcement creates urgency.
FDA AI guidance 2026 developments point toward a model in which context, credibility, documentation, performance, and human oversight matter.
For regulatory affairs, this means AI systems should be explainable enough to support appropriate review and traceability. For medical affairs, it means AI should accelerate evidence workflows without replacing scientific judgment.
Pienomial can help organisations move toward this model by connecting AI capabilities with structured intelligence, evidence, and governed workflows.
The future of pharmaceutical AI will not be determined simply by which companies deploy the most advanced models. It will increasingly be determined by which organisations can demonstrate that their AI systems are useful, explainable, evidence-backed, appropriately governed, and fit for their intended context of use.
